These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 22247700)

  • 1. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.
    Zhou L; Ercolano E; Ammoun S; Schmid MC; Barczyk MA; Hanemann CO
    Neoplasia; 2011 Dec; 13(12):1101-12. PubMed ID: 22247700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
    Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
    Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells.
    Flaiz C; Utermark T; Parkinson DB; Poetsch A; Hanemann CO
    Glia; 2008 Apr; 56(5):506-15. PubMed ID: 18240308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Merlin, a regulator of Hippo signaling, regulates Wnt/β-catenin signaling.
    Kim S; Jho EH
    BMB Rep; 2016 Jul; 49(7):357-8. PubMed ID: 27345717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells.
    Kaempchen K; Mielke K; Utermark T; Langmesser S; Hanemann CO
    Hum Mol Genet; 2003 Jun; 12(11):1211-21. PubMed ID: 12761036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
    Ammoun S; Schmid MC; Ristic N; Zhou L; Hilton D; Ercolano E; Carroll C; Hanemann CO
    Glia; 2012 Nov; 60(11):1721-33. PubMed ID: 22821509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
    Ammoun S; Schmid MC; Triner J; Manley P; Hanemann CO
    Neuro Oncol; 2011 Jul; 13(7):759-66. PubMed ID: 21727212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma.
    Benton D; Yee Chow H; Karchugina S; Chernoff J
    PLoS One; 2024; 19(7):e0305121. PubMed ID: 39083549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
    Ammoun S; Schmid MC; Zhou L; Hilton DA; Barczyk M; Hanemann CO
    Mol Oncol; 2015 Jan; 9(1):236-48. PubMed ID: 25217104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Merlin inhibits Wnt/β-catenin signaling by blocking LRP6 phosphorylation.
    Kim M; Kim S; Lee SH; Kim W; Sohn MJ; Kim HS; Kim J; Jho EH
    Cell Death Differ; 2016 Oct; 23(10):1638-47. PubMed ID: 27285107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma.
    Flaiz C; Ammoun S; Biebl A; Hanemann CO
    Brain Pathol; 2009 Jan; 19(1):27-38. PubMed ID: 18445079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation.
    Bosco EE; Nakai Y; Hennigan RF; Ratner N; Zheng Y
    Oncogene; 2010 Apr; 29(17):2540-9. PubMed ID: 20154721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
    Zhou L; Lyons-Rimmer J; Ammoun S; Müller J; Lasonder E; Sharma V; Ercolano E; Hilton D; Taiwo I; Barczyk M; Hanemann CO
    Oncogene; 2016 Jun; 35(26):3443-53. PubMed ID: 26549023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
    Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
    Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer.
    Morrow KA; Das S; Meng E; Menezes ME; Bailey SK; Metge BJ; Buchsbaum DJ; Samant RS; Shevde LA
    Oncotarget; 2016 Apr; 7(14):17991-8005. PubMed ID: 26908451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
    James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
    Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane.
    Okada T; Lopez-Lago M; Giancotti FG
    J Cell Biol; 2005 Oct; 171(2):361-71. PubMed ID: 16247032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.
    Ammoun S; Hanemann CO
    Nat Rev Neurol; 2011 Jun; 7(7):392-9. PubMed ID: 21647202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.
    Xiao GH; Gallagher R; Shetler J; Skele K; Altomare DA; Pestell RG; Jhanwar S; Testa JR
    Mol Cell Biol; 2005 Mar; 25(6):2384-94. PubMed ID: 15743831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF2/Merlin is required for the axial pattern formation in the Xenopus laevis embryo.
    Zhu X; Min Z; Tan R; Tao Q
    Mech Dev; 2015 Nov; 138 Pt 3():305-12. PubMed ID: 26344136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.